Updates

EKF - Forecasts upgraded again

April 2012

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

The shares burst to a new high after EKF said H2 had beaten expectations.When full year results to 31 December emerged a couple of days later these beat forecasts, which had been upgraded in February, coming out at Â£1.6m ebitda against expectations of Â£1m. Of course these were adjusted for certain exceptionals and the management bonus scheme. The loss before tax was Â£2.4m, including Stanbio acquisition costs. Sales in the year tripled to Â£21.7m but with Stanbio in for six just months and contributing Â£8m, the ongoing sales run rate is now Â£28m. The better H2 was due to a large order for Haemocontrol (HemoPoint H2), an instrument for testing for haemoglobin, from the Mexican Government in November. Th ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Photo-Me

OPG - Splendid news as state electricity prices are hiked 37% in Tamil Nadu

EKF Diagnostics (January 2015)

EKF Diagnostics (October 2014)

EKF Diagnostics (June 2014)

EKF Diagnostics - Three acquisitions in a month (April 2014)

EKF Diagnostics (March 2014)

EKF Diagnostics (October 2013)

EKF Diagnostics (April 2013)

EKF Diagnostics (October 2012)

EKF DIagnostics (October 2011)

EKF - Second large diagnostic deal sends EKF full square into the US market (July 2011)

EKF Diagnostics (December 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X